Trauma is a major cause of death and disability worldwide and despite the introduction of damage control resuscitation^[@R1]^ mortality remains high.^[@R2]^ Approximately one quarter of the trauma patients present with laboratory defined coagulopathy upon admission, and this is associated with a three to fourfold increase in mortality.^[@R3]^ In the literature, laboratory coagulopathy also designated trauma induced coagulopathy (TIC) is described as an over activation of the protein C pathway accompanied by hyperfibrinolysis^[@R4]^ or as representing the hemorrhagic phenotype of disseminated intravascular coagulation.^[@R5]^ Common for both these explanations is that they are based on measuring concentrations of pro- and anticoagulant coagulation factors, platelet count, and fibrin degradation products.

The introduction of the cell based model of hemostasis in the late 1990 s taught us that to adequately assess hemostatic competence whole blood that includes blood cellular elements should be used^[@R6]^ and consequently, assays reflecting this were required. When studying trauma patients at admission with whole blood thrombelastography (TEG), we found that with increasing injury severity, the hemostatic profile became progressively more hypocoagulable and hyperfibrinolytic, which seemed counterintuitive given the substantial risk of exsanguination these patients faced.^[@R7]^ To fully comprehend these findings, we speculated that the endothelium should also be included as a pivotal part of the vascular compartment and we hypothesized that the hemostatic changes observed in whole blood represented an evolutionary adapted response to a potential life-threatening condition.^[@R8]^ The vascular endothelium comprises a single layer of cells that lines every vessel in the body, covers a total surface area of 5000 m^2^ and has a total weight of 1 kg.^[@R9]^ On the luminal part of the endothelium lays the endothelial glycocalyx, a 0.2 to 1 μm thick negatively charged antiadhesive and anticoagulant carbohydrate-rich surface layer that protects the endothelium and maintains vascular barrier function.^[@R10]--[@R12]^ The endothelium is instrumental for balancing hemostasis and for maintaining the homeostasis between the circulating blood and the extravascular space/surrounding tissues.^[@R13],[@R14]^ Furthermore, given the immediate nature of changes in hemostatic competence in severely injured trauma patients we further speculated that activation of the sympathoadrenal activation, with release of large amounts of catecholamines was an important driver of this condition.^[@R8]^

In independent, but small, studies of trauma patients, we found that (i) high circulating syndecan-1, a marker of endothelial glycocalyx degradation,^[@R15]^ was associated with inflammation, hypocoagulability, and increased mortality;^[@R16]^ (ii) the trauma-induced catecholamine surge was closely associated with biomarkers of tissue and endothelial damage, glycocalyx degradation, hypocoagulability including hyperfibrinolysis and independently predicted mortality;^[@R17]^ and (iii) the syndecan-1 levels decreased after resuscitation with plasma.^[@R18]^ We also found that an important determinant of the hypocoagulability observed by whole blood TEG, in these patients, was because of endogenous heparinization induced by the constituents released from the glycocalyx in response to the trauma and shock.^[@R19]^ Collectively, these data indicated that endothelial damage and/or dysfunction significantly contributed to outcome and that sympathoadrenal activation was an important driver of early shock induced coagulopathy.^[@R20]^

Introduction of early administration of plasma and platelets along with red blood cells (RBCs) to trauma patients with severe hemorrhage, not only reduced early deaths caused by exsanguination^[@R21]^ but also led to a reduction in development of multiple organ failure.^[@R22]^ Interestingly, Kozar et al^[@R23]^ found in a rat model of hemorrhagic shock that resuscitation with plasma, as opposed to normal saline, had an endothelial- and glycocalyx rejuvenating effect related to increased mRNA levels of Syndecan-1 in the endothelial cells. More recently, adiponectin was identified as an important component in FFP to attenuate endothelial damage and improve lung vascular barrier function in mice after shock and resuscitation and collectively, these data suggest a pivotal role of the endothelium for outcome in trauma patients with hemorrhagic shock.^[@R24],[@R25]^

The aim of the current study was therefore to validate and confirm our preliminary findings presented above in a larger, and independent, cohort of trauma patients and to more comprehensively characterize the endothelium by analyzing also soluble thrombomodulin (sTM), an endothelial cell damage marker, and soluble E-selectin (sE-selectin), an endothelial cell activation marker, which both have been significantly associated with poor outcome in patients with other types of acute critical illness.^[@R26]--[@R28]^

METHODS
=======

Setting and Patients
--------------------

This prospective observational study was conducted under an approved Institutional Review Board (IRB) (Universal Study, HSC-GEN-12--0059), which included all adult trauma patients (≥16 yrs) at the highest level of activation at Memorial Hermann Hospital Texas Medical Center (MHH-TMC). The criteria for highest activation include: Glasgow Coma Score ≤10, heart rate \>120 beats per minute, systolic blood pressure ≤90, respiratory rate \<10 or \>29 per minute, intubation, penetrating injury to torso, groin, head or neck, amputation proximal to ankle or wrist, paraplegia, quadriplegia, uncontrolled external hemorrhage, fracture to pelvis or two or more long bone fractures, and receiving blood en route. The study took place over 18 months from March 2012 to September 2013. This was an opportunistic prospective study that ran parallel to three other clinical studies at MHH-TMC; patients admitted to the other studies were not included in this analysis. Samples were collected when research staff was not directly involved in the other studies and available to process the samples. The IRB approval was obtained for delayed consent, obtained from the patient or their legally authorized representative within 72 hours of admission, or as soon as possible. For patients who were discharged or died within 24 hours of admission, a waiver of consent was obtained. If consent could not be obtained, the patient was excluded from the study and their blood samples destroyed. The study excluded pregnant women and prisoners.

In the current study, plasma biomarkers from a total of 561 patients were investigated. Of these, only patients suffering from blunt or penetrating injury were included with the requirement that data on ISS and adrenaline, noradrenaline, syndecan-1, and thrombomodulin were available. This excluded burn injury patients (n = 64) and an additional 73 patients \[ie, nontrauma (n = 2), missing ISS (n = 42), and missing biomarkers (n = 29)\]. The excluded nonburn injury patients (n = 73) did not differ significantly from the 424 included patients with regard to age median 43 years (interquartile range, IQR 27--55), sex (73% males), and \<24-hours, 7-day, and 28-day mortality (4%, 14%, and 15%, respectively).

Clinical Data and Blood Samples
-------------------------------

Information on baseline demography, clinical, physiologic, and laboratory tests were retrospectively collected from patient records and the institutional trauma registry. The data included admission vital signs, blood count test results, pH, base excess (BE), conventional plasma based coagulation tests \[prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR)\], prehospital fluids, 24-hour blood transfusions (packed RBCs, plasma, and apheresis platelets), 24-hour crystalloid infusions, complications, injury severity score (ISS), and patient outcomes (mortality up to 28 days).

Blood samples were collected in citrated tubes from each patient immediately upon hospital admission. Patients from whom blood samples could not be obtained were excluded from analysis. Upon hospital admission, 20 mL of blood was obtained. Blood was transferred into vacutainer tubes containing 3.2% citrate and inverted to ensure proper anticoagulation. After spinning, plasma was aliquoted and frozen for later analysis. The enzyme linked immunosorbent assay (ELISA) analyses were conducted by trained laboratory technicians, according to the manufactures recommendations at the Hemostasis Research Laboratory, Section for Transfusion Medicine, Capital Region Blood Bank, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

ELISA
-----

Soluble biomarkers of sympathoadrenal activation (adrenaline, noradrenaline), endothelial cell activation (sE-selectin),^[@R29],[@R30]^ endothelial glycocalyx (syndecan-1),^[@R15]^ and cell (thrombomodulin)^[@R29]--[@R31]^ damage were measured by commercially available immunoassays in EDTA plasma according to the manufactures recommendations. Adrenaline and noradrenaline (2-CAT ELISA, Labor Diagnostica Nord GmbH & Co. KG, Nordhorn, Germany) have lower limit of detection (LLD) 10 pg/mL (adrenaline, normal reference \<100 pg/mL) and 50 pg/mL (noradrenaline, normal reference \<600 pg/mL), respectively. Syndecan-1 (Diaclone Nordic Biosite, Copenhagen, Denmark) has LLD 4.94 ng/mL, soluble thrombomodulin (sTM, Nordic Biosite, Copenhagen, Denmark) has LLD 0.31 ng/mL, sE-selectin (IBL International GMBH, Hamburg, Germany) has LLD 0.3 ng/mL, and sVE-cadherin (R&D Systems Europe, Ltd., Abingdon, UK) has LLD 0.113 ng/mL.

Statistics
----------

Statistical analysis was performed using SAS 9.4 (SAS Institute Inc., Cary, NC) and SPSS 22 (IBM Corporation, New York, NY).

Simple correlations were investigated by Pearson correlations with results displayed as the product-moment correlation coefficient Pearson\'s r (or r^2^) and *P* values. To investigate the independent association between sympathoadrenal activation and endothelial glycocalyx and cell damage (syndecan-1, thrombomodulin, and sE-selectin), univariate and multivariate adjusted linear regression analysis were performed, including variables that were either found to correlate with or were expected to influence endothelial damage: age, ISS, GCS, SBP, BE, platelet count, hemoglobin, prehospital plasma, and administered prehospital fluids (Table [2](#T2){ref-type="table"}). Results are presented as regression coefficients (β) with 95% confidence intervals (CI) and *P* values.

The predictive value of sympathoadrenal activation (adrenaline, noradrenaline) and endothelial damage (syndecan-1, thrombomodulin) for \<24-hour, 7-day, and 28-day mortality was investigated by univariate and multivariate adjusted Cox proportional-hazards models, the latter after adjusting for age, sex, ISS, GCS, BE, platelet count, and hemoglobin. Data are presented as relative hazard ratio (HR) with 95% CI, Walds *χ*^*2*^ and *P* values. To reveal the influence of missing values on the results, multiple imputation analysis (five imputed dataset and a merge of these) were conducted and the linear regression analysis and Cox proportional-hazards models were repeated on imputed data. This did not change the results for any of the analyses and results from the raw data are displayed in the manuscript. Data are presented as medians with IQR or as n (proportions). *P* values \<0.05 were considered significant.

RESULTS
=======

Patients
--------

A total of 424 patients were included in the current study with a median age of 40 years, 77% were male, median ISS was 17, and 72% suffered from blunt injury (Table [1](#T1){ref-type="table"}). Further details on demography, injury severity and type, admission physiology, biomarker levels, transfusions, and outcome are displayed in Table [1](#T1){ref-type="table"}.

Sympathoadrenal Activation and Endothelial Damage
-------------------------------------------------

To investigate the association between sympathoadrenal activation and endothelial damage, we investigated simple correlations between catecholamine levels and biomarkers reflecting endothelial damage followed by linear regression analysis.

By simple correlations, plasma adrenaline and noradrenaline correlated with plasma syndecan-1 (r = 0.38, *P* \< 0.001 and r = 0.23, *P* \< 0.001, respectively) whereas neither adrenaline nor noradrenaline correlated with thrombomodulin (r = 0.06, *P* = 0.213 and r = 0.07, *P* = 0.149, respectively) or sE-selectin (r = --0.09, *P* = 0.094 and r = --0.01, *P* = 0.886, respectively). When stratifying patients according to injury type, the correlation between plasma adrenaline and syndecan-1 levels persisted within in both blunt (r = 0.43, *P* \< 0.001) and penetrating (r = 0.24, *P* = 0.013) injury patients.

By linear regression analysis, univariate predictors of higher syndecan-1 were higher ISS and lower GCS, SBP, BE, platelet count and hemoglobin, and prehospital plasma and higher adrenaline but in the adjusted model, higher plasma adrenaline was the only independent predictor of higher syndecan-1 levels (Table [2](#T2){ref-type="table"}). Univariate predictors of higher thrombomodulin were higher age and ISS and lower BE and hemoglobin (whereas adrenaline was not) but only higher age and lower hemoglobin were independent predictors of higher thrombomodulin (Table [2](#T2){ref-type="table"}). We did not perform linear regression analysis for sE-selectin as this biomarker neither correlated with catecholamines nor were predictive for mortality (see below).

As depicted in Figure [1](#F1){ref-type="fig"}, the combined highest level plasma adrenaline, injury severity, shock, inhospital transfusion, and 28-day mortality were associated with excessively increased syndecan-1 levels (Figure [1](#F1){ref-type="fig"}A--D).

![3-D plots displaying associations between plasma adrenaline, injury severity, base excess, transfusions, mortality, and plasma levels of endothelial glycocalyx damage in 424 trauma patients admitted to a Level I Trauma Centre in the United States. Injury severity score (ISS) were categorized into four groups (ISS \<9, ISS 9--15, ISS 16--25, and ISS \>25) and plasma adrenaline were categorized into quartiles (Q1 28 pg/mL (IQR 16--28), Q2 93 pg/mL (IQR 77--124), Q3 263 pg/mL (IQR 217--316), and Q4 884 pg/mL (IQR 659--1901). Transfusions refers to inhospital transfusions (yes, no). The 3-D plots display: (A) ISS, adrenaline quartile, and syndecan-1 (ng/mL); (B) Base excess, adrenaline quartile, and syndecan-1 (ng/mL); (C) Transfusions, adrenaline quartile, and syndecan-1 (ng/mL); and (D) 28-day mortality, adrenaline quartiles, and syndecan-1 (ng/mL).](ansu-265-597-g001){#F1}

Outcome
-------

The predictive value of sympathoadrenal activation and endothelial damage for mortality was investigated by univariate and adjusted Cox proportional-hazards models.

In the Cox proportional-hazards analyses, higher age, higher ISS, and lower GCS, BE and hemoglobin, and higher adrenaline, noradrenaline (*P* = 0.007, *P* = 0.137, and *P* = 0.032, respectively) syndecan-1 and thrombomodulin levels were univariate predictors of \<24-hour, 7-day, and 28-day mortality. The only exceptions were that GCS did not predict \<24-hours mortality; noradrenaline did not predict 7-day mortality and hemoglobin did not predict 7-day and 28-day mortality (Table [3](#T3){ref-type="table"}). Plasma sE-selectin did not predict mortality (data not shown).

In the adjusted models, only adrenaline and syndecan-1 were independent biomarker predictors of early \<24-hour mortality together with age and BE (Table [3](#T3){ref-type="table"}). Adrenaline, syndecan-1, and thrombomodulin levels were independent predictors of 7-day and 28-day mortality together with age (Table [3](#T3){ref-type="table"}). In the adjusted models, noradrenaline predicted \<24-hours mortality (*P* = 0.048) but not 7-day or 28-day mortality (data not shown).

DISCUSSION
==========

The main findings of the current study were that plasma catecholamine levels at admission correlated with circulating levels of syndecan-1, an endothelial glycocalyx constituent, and that adrenaline levels independently predicted higher syndecan-1 levels---that is, a surrogate marker of glycocalyx degradation (endotheliopathy of trauma). Furthermore, admission adrenaline and syndecan-1 were independent predictors of both early and late mortality.

The finding here of an independent association between higher syndecan-1 levels and mortality of trauma patients underscores the importance of the state of the endothelium and its related constituents for outcome in these critically ill patients, and is in alignment with our previous findings in smaller cohorts of trauma patients.^[@R16],[@R17]^ The results are also in agreement with findings in other patient groups facing acute critical illness. In a large cohort of patients with varying degrees of sepsis, we found a dose-dependent increase in syndecan-1 levels with increased sepsis severity and mortality.^[@R26]^ Moreover, syndecan-1 was here independently associated with organ failure, such as hepatic and renal failure.^[@R26]^ In patients with acute myocardial infarction, being an acute critical illness though with minute tissue damage but where cardiogenic shock have systemic manifestations, we also found that higher syndecan-1 levels were independently associated with increased all-cause mortality at 30 days.^[@R27]^ From a pathophysiological and mechanistic point of view, it could be speculated that the increased shedding of glycocalyx results in an increased activation and damage of the endothelial cells resulting in a prothrombotic phenotype that leads to microvascular thrombosis and ensuing organ failure.^[@R8]^ Here, this is supported by an independent association of the endothelial cellular damage marker sTM and increased 7-day and 28-day mortality. Johansen et al^26^ reported in patients with sepsis that the level of sTM independently predicted organ failure of the liver and the kidneys and multiorgan failure and mortality; and in resuscitated out of hospital cardiac arrest patients, sTM was also a strong and independent predictor of 30-day mortality.^[@R28]^ Moreover, loss of endothelial integrity causes capillary leakage with fluid extravasation, hypotension and shock, and in the current study we found that lower systolic blood pressure and BE were strongly associated with circulating syndecan-1, supporting this notion.

Traumatic injury immediately activates the sympathoadrenal system with release of large amounts of catecholamines that exert widespread dose-dependent effects on metabolism and the vascular system.^[@R32],[@R33]^ We proposed that patients with excessive trauma activation, the sympathoadrenal system becomes maladaptive and contribute to organ damage.^[@R8]^ Thus, in high concentrations, catecholamines directly damage the endothelium resulting in local edema, endothelial cell swelling, necrosis, and progressive deendothelialization.^[@R34]^ In the current study, we found that plasma catecholamines correlated strongly with plasma syndecan-1 and higher adrenaline was the only independent predictor of higher syndecan-1 levels. Moreover, the combined highest level plasma adrenaline, injury severity, and transfusions (and mortality) was associated with excessively increased syndecan-1, confirming our previous findings that sympathoadrenal activation is of critical importance for development of traumatic endotheliopathy. Furthermore, adrenaline and syndecan-1 were independent predictors of early \<24-hours mortality and late 7-day and 28-day mortality, whereas sTM only independently predicted 7-day and 28-day mortality. The finding here, of a strong correlation between levels of catecholamines upon admission and outcome, is in alignment with findings from other patient groups suffering from acute critical illness. In patients resuscitated from out-of-hospital cardiac arrest, we reported that high plasma adrenaline was associated with increased 7-day, 30-day, and 180-day mortality.^[@R28]^ Similarly, in patients with acute myocardial infarction, stratified into quartiles based on plasma adrenaline levels, one quartile higher plasma adrenaline was independently associated with both increased 30-day and long-term mortality.^[@R27]^ In patients with varying degree of infection, including sepsis, we also found that catecholamines together with syndecan-1 and sTM independently predicted increased 28-day mortality.^[@R28]^

According to our proposed hypothesis, sympathoadrenal activation is a pivotal driver of the traumatic endotheliopathy, so modulation of this response by limiting the catecholamine surge, is expected to be beneficial for outcome in these patients. Interestingly, Bukur et al^[@R35]^ recently reported that in 663 critically injured patients (ISS≥25) admitted to the intensive care unit, those 98 patients receiving beta-blockers upon admission, had significantly lower inhospital mortality (11% vs 19%, *P* = 0.006). Stepwise logistic regression identified beta-blocker use as an independent protective factor for mortality these patients. Similarly, Cotton et al^[@R36]^ reported that in patients with severe traumatic brain injury, beta-blocker exposure before the trauma was associated with a significant reduction in mortality, which was even more impressive, considering that the group on beta-blocker therapy was older, more severely injured, and had lower predicted survival than the comparators.^[@R36]^ Together, these findings support that downstream effects of excessive sympathoadrenal activation may also be harmful in shocked patients ^[@R8],[@R37]^ making it tempting to speculate if low-dose beta-blockers may be beneficial in these patients.

The current study has important limitations inherent to its design. Being an observational study precludes from cause and effect conclusions but merely points towards significant associations that requires further investigation. Moreover, as a single-center study, this limits the generalizability of the results, although our findings here support previous reports from independent trauma cohorts.^[@R16],[@R18],[@R19]^ Furthermore, the selection of biomarkers analyzed in this study does not preclude that other markers may also be of importance for the development and progression of traumatic endotheliopathy. Unique for the current study ∼10% of the patients received transfusions prehospital and the median prehospital crystalloid use was 0. This may have influenced the levels of endothelial biomarkers at admission given that administration of crystalloids has been shown to increase the circulating levels of these markers and contribute to endothelial damage.

In conclusion, the finding of the current study supports the critical role of endotheliopathy for outcome in severely traumatized patients and that sympathoadrenal activation is an important driver of this condition. Future randomized controlled trials investigating the effect of sympathoadrenal modulation and endothelial protection and repair are highly warranted.
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###### 

Demography, Injury Type and Severity, Admission Physiology, Biomarker Levels, Transfusions, and Outcome in 424 Prospectively Enrolled Trauma Patients Admitted to a Level I Trauma Centre in the United States

                                          Unit                Median (IQR)
  --------------------------------------- ------------------- --------------------------------------------
  Demography                                                  
   N                                                          424
   Age                                    yrs                 40 (27--55)
   Sex                                    male \[n (%)\]      326 (76.9%)
   Race                                   W / BL /H /Others   231 (54%) / 67 (16%) / 103 (24%) / 23 (6%)
  Injury type and severity                                    
   MOI                                    Blunt injury        306 (72%)
   ISS                                    score               17 (9--26)
   Severe TBI (AIS head ≥3)               n (%)               180 (42%)
   GCS                                    score               12 (3--15)
   Transfer                               n (%)               168 (40%)
   Mode of Transport                      HEL/AMB/Others      238 (56%) / 168 (40%) / 18 (4%)
  Admission physiology and biochemistry                       
   SBP (ED)                               mmHg                124 (106--142)
   BE (ED)                                mEq/L               −3 (-6--1)
   pH (ED)                                                    7.32 (7.25--7.37)
   Platelet count (ED)                    10^9^/L             220 (180--269)
   Hemoglobin (ED)                        g/dL                13.1 (11.9--14.4)
   PT                                     sec                 14.2 (13.4--15.3)
   INR                                    ratio               1.1 (1--1.2)
   aPTT                                   sec                 29.2 (26.3--32.5)
  Biomarkers                                                  
   Adrenaline                             pg/mL               162 (53--364)
   Noradrenaline                          pg/mL               848 (332--1501)
   Syndecan-1                             ng/mL               25 (13--60)
   Thrombomodulin                         ng/mL               5.2 (3.84--7.19)
   sE-selectin                            ng/mL               39 (23--58)
  Transfusions                                                
   Transfused                             n (%)               138 (61.1%)
   RBC (prehospital)                      n (%)               38 (10.4%)
   Plasma (prehospital)                   n (%)               29 (7.9%)
   Platelets (prehospital)                n (%)               0 (0%)
   Crystalloids (prehospital)             n (%)               156 (39.6%)
   Crystalloids volume (prehospital)      mL                  0 (0--200)
  Outcome                                                     
   Hospital LOS                           days                5 (1--15)
   ICU LOS                                days                1 (0--5)
   Ventilator                             days                1 (0--3)
   Mortality (\<24 hrs)                   n (%)               19 (4.9%)
   Mortality (7days)                      n (%)               62 (16.1%)
   Mortality (28 days)                    n (%)               73 (17.2%)

Data are presented as medians (IQR) or n (%).

AIS head \>3.

AIS indicates Abbreviated Injury Score; AMB, ambulance; aPTT, activated partial thromboplastin time; BE, base excess; BL, Blacks; ED, emergency department; GCS, Glascow Coma Scale; H, Hispanics; HEL, helicopter; ICU, intensive care unit; INR, international normalized ratio; IQR, interquartile range; ISS, injury severity score; LOS, length of stay; MOI, mechanism of injury; PH, prehospital; PT, prothrombin time; RBC, red blood cells; SBP, systolic blood pressure; TBI, severe traumatic brain injury; W, Whites.

###### 

Univariate and Multivariate Linear Regression Analysis of Variables Associated With Circulating Levels of Biomarkers Reflecting Endothelial Glycocalyx and Cell Damage in 424 Trauma Patients Trauma Patients Admitted to a Level I Trauma Centre in the United States

                                               Predictors of Syndecan-1           Predictors of Thrombomodulin                                                               
  ---------------------------- --------------- -------------------------- ------- ------------------------------ ------- --------------------- ------- --------------------- -------
  Age                          10 yrs          0.45 (−4.25--5.16)         0.851   0.34 (−4.01--4.68)             0.879   0.36 (0.20--0.52)     0.000   0.32 (0.15--0.5)      0.000
  ISS (ED)                     1 point         1.73 (1.06--2.41)          0.000   0.48 (−0.30--1.25)             0.229   0.03 (0.00--0.05)     0.019   0.00 (−0.03--0.03)    0.890
  GCS (ED)                     1 point         −1.92 (−3.49--0.36)        0.016   0.17 (−1.48--1.83)             0.837   −0.05 (−0.10--0.01)   0.088   −0.01 (−0.07--0.06)   0.879
  SBP (ED)                     10 mmHg         −6.23 (−8.93--3.53)        0.000   −2.69 (−5.51--0.14)            0.062   −0.03 (−0.13--0.06)   0.507   −0.01 (−0.12--0.1)    0.857
  BE (ED)                      1 mEg/L         −4.24 (−5.9--2.58)         0.000   −0.91 (−2.73--0.91)            0.325   −0.07 (−0.13--0.01)   0.029   −0.03 (−0.11--0.04)   0.375
  Platelet count (ED)          10^\*^10^9^/L   −1.31 (−2.36--0.26)        0.014   −0.62 (−1.62--0.37)            0.220   −0.04 (−0.07--0.00)   0.068   −0.03 (−0.07--0.01)   0.113
  Hemoglobin (ED)              1 g/dL          −5.15 (−9.41--0.89)        0.018   −2.17 (−6.31--1.98)            0.305   −0.19 (−0.34--0.04)   0.014   −0.17 (−0.33--0.00)   0.048
  Plasma (prehospital)         1 unit          42.48 (19.22--65.75)       0.000   6.02 (−16.78--28.81)           0.604   0.72 (−0.15--1.59)    0.104   0.36 (−0.55--1.27)    0.432
  Crystalloids (prehospital)   100 mL          1.23 (−0.47--2.93)         0.155   −0.64 (−2.55--1.27)            0.508   −0.01 (−0.07--0.05)   0.758   −0.01 (−0.09--0.06)   0.758
  Adrenaline                   100 pg/mL       3.68 (2.79--4.57)          0.000   2.75 (1.54--3.96)              0.000   0.02 (−0.01--0.06)    0.213   0.02 (−0.02--0.07)    0.328

Regression coefficients (β) with 95% CI and *P* (and R, for the multivariate models) are displayed. Predicted change in plasma syndecan-1 (ng/mL) or soluble thrombomodulin (ng/mL) levels associated with one unit increase in: Age (10 yrs older), ISS 1 point higher, GCS score, SBP 10 mmHg higher, BE 1 mEq/L higher, 1 point higher, platelet count (10 platelets^\*^10^9^/L higher), hemoglobin 1 g/dL higher, plasma (prehospital, per 1 unit transfused), crystalloids volume (prehospital, per 100 mL administered) and plasma adrenaline level (100 pg/mL higher).

BE indicates base excess; CI, confidence intervals; ED, emergency department; GCS, Glascow Coma Scale; ISS, injury severity score; SBP, systolic blood pressure.

###### 

Univariate and Multivariate Cox Proportional Hazards Models of Variables Associated With 24-Hours, 7-Day, and 28-Day Mortality in 424 Trauma Patients Trauma Patients Admitted to a Level I Trauma Centre in the United States

                                         Covariable          Biomarker: Adrenaline   Biomarker: Syndecan-1   Biomarker: Thrombomodulin                                                                                    
  ---------------------- --------------- ------------------- ----------------------- ----------------------- --------------------------- ------ --------- ------------------- ------ --------- ------------------- ------ ---------
  \<24-hour mortality                                                                                                                                                                                                     
   Biomarker             Univariate                                                                          1.06 (1.03--1.09)           19.0   \<0.001   1.06 (1.03--1.09)   18.0   \<0.001   1.09 (0.98--1.21)   2.5    0.116
   Biomarker             Adjusted                                                                            1.06 (1.02--1.09)           10.5   0.001     1.04 (1.00--1.08)   3.9    0.047     1.03 (0.9--1.17)    0.2    0.674
   Age                   10 Yrs          1.26 (1.02--1.57)   4.5                     0.034                   1.30 (1.02--1.66)           4.5    0.035     1.2 (0.95--1.51)    2.3    0.132     1.20 (0.95--1.51)   2.3    0.131
   Sex                   Male            0.52 (0.20--1.31)   1.9                     0.163                   0.69 (0.23--2.10)           0.4    0.519     0.7 (0.25--1.97)    0.5    0.495     0.78 (0.28--2.19)   0.2    0.636
   ISS                   1 Point         1.03 (1.00--1.06)   4.1                     0.042                   1.00 (0.96--1.04)           0.0    0.833     1.00 (0.96--1.04)   0.0    0.994     1.01 (0.97--1.05)   0.2    0.690
   GCS (ED)              1 Point         0.92 (0.85--1.01)   3.3                     0.070                   0.98 (0.88--1.08)           0.2    0.627     0.98 (0.88--1.08)   0.2    0.673     0.98 (0.89--1.09)   0.1    0.726
   BE (ED)               1 mEq/L         0.90 (0.84--0.95)   12.7                    \<0.001                 0.93 (0.86--1.01)           2.9    0.088     0.94 (0.88--1.00)   3.3    0.069     0.92 (0.86--0.98)   6.4    0.012
   Platelet count (ED)   10\*10^9^/L     0.94 (0.88--1.00)   3.6                     0.058                   0.97 (0.9--1.04)            0.9    0.348     0.97 (0.91--1.04)   0.6    0.439     0.96 (0.90--1.03)   1.1    0.295
   Hemoglobin (ED)       1 g/dL          0.83 (0.69--1.00)   4.0                     0.046                   0.96 (0.76--1.23)           0.1    0.767     0.96 (0.76--1.22)   0.1    0.758     0.95 (0.75--1.22)   0.1    0.710
  7-day mortality                                                                                                                                                                                                         
   Biomarker             Univariate                                                                          1.06 (1.04--1.08)           34.3   \<0.001   1.04 (1.02--1.06)   12.9   \<0.001   1.11 (1.05--1.17)   13.9   \<0.001
   Biomarker             Adjusted                                                                            1.06 (1.03--1.08)           25.1   \<0.001   1.03 (1.00--1.05)   4.9    0.027     1.07 (1.00--1.14)   4.3    0.037
   Age                   10 Yrs          1.48 (1.30--1.67)   37.5                    \<0.001                 1.46 (1.28--1.67)           30.8   \<0.001   1.44 (1.26--1.64)   28.2   \<0.001   1.4 (1.23--1.61)    24.3   \<0.001
   Sex                   Male            0.61 (0.36--1.04)   3.3                     0.070                   0.68 (0.38--1.23)           1.6    0.207     0.83 (0.47--1.47)   0.4    0.529     0.84 (0.47--1.48)   0.4    0.539
   ISS                   1 Point         1.03 (1.02--1.05)   15.7                    \<0.001                 1.00 (0.98--1.02)           0.2    0.692     1.01 (0.99--1.03)   2.0    0.158     1.02 (1.00--1.04)   3.8    0.051
   GCS (ED)              1 Point         0.94 (0.90--0.98)   7.5                     0.006                   0.96 (0.91--1.01)           2.7    0.099     0.97 (0.92--1.02)   1.2    0.272     0.97 (0.92--1.03)   1.0    0.307
   BE (ED)               1 mEq/L         0.95 (0.91--1.00)   4.3                     0.038                   1.00 (0.94--1.05)           0.0    0.865     0.97 (0.93--1.02)   1.3    0.250     0.97 (0.93--1.02)   1.4    0.241
   Platelet count (ED)   10\*10^9^/L     0.97 (0.94--1.01)   2.8                     0.094                   0.97 (0.94--1.01)           2.4    0.124     0.98 (0.95--1.02)   1.0    0.312     0.98 (0.95--1.02)   0.9    0.339
   Hemoglobin (ED)       1 g/dL          0.91 (0.82--1.02)   2.5                     0.117                   0.98 (0.86--1.11)           0.1    0.724     1.00 (0.88--1.14)   0.0    0.976     1.00 (0.88--1.13)   0.0    0.996
  28-day mortality                                                                                                                                                                                                        
   Biomarker             Univariate                                                                          1.05 (1.03--1.07)           36.5   \<0.001   1.04 (1.02--1.06)   14.3   \<0.001   1.10 (1.04--1.15)   12.3   \<0.001
   Biomarker             Adjusted                                                                            1.06 (1.04--1.08)           27.5   \<0.001   1.03 (1.00--1.05)   5.2    0.022     1.06 (1.00--1.13)   3.9    0.049
   Age                   10 Yrs          1.41 (1.26--1.59)   34.3                    \<0.001                 1.41 (1.24--1.60)           28.9   \<0.001   1.39 (1.23--1.58)   27.4   \<0.001   1.36 (1.20--1.54)   22.7   \<0.001
   Sex                   Male            0.63 (0.38--1.03)   3.4                     0.066                   0.66 (0.38--1.15)           2.2    0.139     0.83 (0.49--1.43)   0.4    0.507     0.82 (0.48--1.4)    0.5    0.460
   ISS                   1 Point         1.03 (1.02--1.05)   15.4                    \<0.001                 1.00 (0.98--1.02)           0.0    0.841     1.01 (0.99--1.03)   1.9    0.171     1.02 (1.00--1.04)   3.4    0.065
   GCS (ED)              1 Point         0.94 (0.90--0.98)   8.5                     0.004                   0.96 (0.91--1.00)           3.3    0.070     0.97 (0.92--1.02)   1.6    0.203     0.97 (0.93--1.02)   1.3    0.250
   BE (ED)               1 mEq/L         0.96 (0.92--1.01)   2.8                     0.097                   1.01 (0.96--1.07)           0.3    0.583     0.98 (0.94--1.03)   0.6    0.442     0.98 (0.94--1.03)   0.5    0.463
   Platelet count (ED)   10^\*^10^9^/L   0.97 (0.94--1)      2.9                     0.090                   0.97 (0.94--1.01)           2.7    0.098     0.98 (0.95--1.01)   1.2    0.270     0.98 (0.95--1.01)   1.2    0.284
   Hemoglobin (ED)       1 g/dL          0.92 (0.83--1.02)   2.3                     0.132                   1.00 (0.89--1.13)           0.0    0.953     1.01 (0.90--1.13)   0.0    0.862     1.01 (0.90--1.14)   0.0    0.830

Relative hazards (HR) with 95% CI, Wald and *P* values are displayed. The HR (95% CI) are associated with one unit increase in: Age (10 yrs older), Sex (male sex), ISS 1 point higher, GCS 1 point higher, BE 1 mEq/L higher, platelet count (10 platelets^\*^10^9^/L higher), hemoglobin (1 g/dL higher) and either adrenaline (100 pg/mL higher), syndecan-1 (10 ng/mL), and thrombomodulin (1 ng/mL higher).

BE indicates base excess; CI, confidence intervals; ED, emergency department; GCS, Glascow Coma Scale; ISS, injury severity score; SBP, systolic blood pressure.
